{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:51Z","timestamp":1781636211853,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Regional Development Fund for Science and Innovation","award":["BES- 2016-078288"],"award-info":[{"award-number":["BES- 2016-078288"]}]},{"name":"European Regional Development Fund for Science and Innovation","award":["PRE2020-093423"],"award-info":[{"award-number":["PRE2020-093423"]}]},{"name":"European Regional Development Fund for Science and Innovation","award":["SAF2015-66015-R and PID2019-110758RB-I00 and PID2023-147517OB-I00"],"award-info":[{"award-number":["SAF2015-66015-R and PID2019-110758RB-I00 and PID2023-147517OB-I00"]}]},{"DOI":"10.13039\/100008055","name":"Fundaci\u00f3n Eugenio Rodr\u00edguez Pascual","doi-asserted-by":"publisher","award":["FERP-2022-79"],"award-info":[{"award-number":["FERP-2022-79"]}],"id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PRDMA19024LODE"],"award-info":[{"award-number":["PRDMA19024LODE"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["POSTD19036MORA"],"award-info":[{"award-number":["POSTD19036MORA"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES222946GARC"],"award-info":[{"award-number":["INVES222946GARC"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["TRNSC213883DUEN and Transcan-3 JTC2022"],"award-info":[{"award-number":["TRNSC213883DUEN and Transcan-3 JTC2022"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia Grant","award":["SFRH\/BD\/144241\/2019"],"award-info":[{"award-number":["SFRH\/BD\/144241\/2019"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC22\/00015"],"award-info":[{"award-number":["AC22\/00015"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERONC no. CB16\/12\/00228"],"award-info":[{"award-number":["CIBERONC no. CB16\/12\/00228"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BC) remains a major clinical challenge owing to its high recurrence, limited treatment options, and molecular heterogeneity. Despite recent therapeutic advances, prognosis remains poor and resistance to treatment is common, underscoring the need for improved experimental models to study tumorigenesis and therapeutic response. A critical obstacle in advanced BC research is the scarcity of in vivo models that accurately replicate invasive and metastatic behavior and serve as robust preclinical tools for evaluating new therapies, especially in immunocompetent settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To assess how the cell of origin and specific driver genes influence bladder tumorigenesis and subtype specification, we engineered four genetically modified mouse models of advanced BC. Two combinations of tumor suppressor genes\u2014either\n                      <jats:italic>Pten<\/jats:italic>\n                      and\n                      <jats:italic>Trp53<\/jats:italic>\n                      , or\n                      <jats:italic>Pten<\/jats:italic>\n                      ,\n                      <jats:italic>Trp53<\/jats:italic>\n                      ,\n                      <jats:italic>Rb1<\/jats:italic>\n                      , and\n                      <jats:italic>Rbl1<\/jats:italic>\n                      \u2014 were targeted either basal or suprabasal urothelial cells via intravesical Cre-adenovirus delivery. From tumors arising in these models, we derived multiple cell lines and established syngeneic graft models. Both genetically engineered mouse models and derived mouse cell lines were extensively characterized and transcriptionally compared with advanced human BC and human BC cell lines, and were further utilized as preclinical platforms to evaluate therapeutic responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Loss of the retinoblastoma gene family reduced cancer-specific survival and was associated with more differentiated carcinomas. In both genetic backgrounds, luminal-derived tumors appeared earlier but displayed fewer metastatic events. Histopathological and transcriptomic analyses revealed that these tumors resemble human basal-squamous and stroma-rich subtypes, sharing regulatory networks and activated signaling pathways with human invasive BC. Tumors lacking retinoblastoma family genes exhibited enhanced immune infiltration, reinforcing their value for diverse preclinical applications. To overcome detection and latency limitations, we established syngeneic graft models from tumor-derived cell lines. These models were validated as preclinical platforms, exhibiting therapeutic responses to CDK4\/6 inhibition and anti-PD-L1 immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These novel mouse models faithfully recapitulate key molecular, histological, and immune features of human invasive BC. They represent versatile and clinically relevant preclinical models for dissecting disease progression mechanisms and evaluating emerging therapeutic strategies within an intact immune environment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03677-8","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T03:16:25Z","timestamp":1771816585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models"],"prefix":"10.1186","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2494-7587","authenticated-orcid":false,"given":"Ester","family":"Munera-Maravilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1884-3773","authenticated-orcid":false,"given":"Mercedes","family":"P\u00e9rez-Escavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-2297","authenticated-orcid":false,"given":"Carolina","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-8249","authenticated-orcid":false,"given":"Iris","family":"Lodewijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-037X","authenticated-orcid":false,"given":"Sandra P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1626-3978","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Mart\u00edn de Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-2503","authenticated-orcid":false,"given":"Ignacio","family":"A. Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-1442","authenticated-orcid":false,"given":"Luc\u00eda","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-0626","authenticated-orcid":false,"given":"V\u00edctor G.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"\u00c1lvarez-Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-9726","authenticated-orcid":false,"given":"Marta","family":"Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-3177","authenticated-orcid":false,"given":"Jes\u00fas M.","family":"Paramio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-1596","authenticated-orcid":false,"given":"Cristian","family":"Su\u00e1rez-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"3677_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3677_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58.","journal-title":"Nat Rev Dis Primers"},{"key":"3677_CR3","unstructured":"National Cancer Institute. U.S. Department of Health and Human Services. 2023. Bladder Cancer Prognosis and Survival Rates."},{"issue":"10","key":"3677_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"5","key":"3677_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","volume":"36","author":"T Powles","year":"2025","unstructured":"Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025;36(5):561\u201371.","journal-title":"Ann Oncol"},{"issue":"4","key":"3677_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"issue":"3","key":"3677_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540\u2013e55625.","journal-title":"Cell"},{"issue":"4","key":"3677_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/BLC-180175","volume":"4","author":"MA Ingersoll","year":"2018","unstructured":"Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM. Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. Bladder Cancer. 2018;4(4):429\u201340.","journal-title":"Bladder Cancer"},{"issue":"1","key":"3677_CR9","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1038\/s41467-024-52915-0","volume":"15","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al. The genomic and transcriptomic landscape of metastastic urothelial cancer. Nat Commun. 2024;15(1):8603.","journal-title":"Nat Commun"},{"issue":"1","key":"3677_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-021-08078-y","volume":"21","author":"RG Manzano","year":"2021","unstructured":"Manzano RG, Catalan-Latorre A, Brugarolas A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer. 2021;21(1):432.","journal-title":"BMC Cancer"},{"issue":"1","key":"3677_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc3858","volume":"15","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15(1):42\u201354.","journal-title":"Nat Rev Cancer"},{"key":"3677_CR12","doi-asserted-by":"crossref","unstructured":"Constantin T, P\u0103v\u0103lean M, Bucur \u0218tefana, Constantin MM, Nicolescu AC, Pacu I et al. Anim Models Bladder Cancer Biomedicines. 2021;9(12).","DOI":"10.3390\/biomedicines9121762"},{"issue":"12","key":"3677_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41585-024-00885-9","volume":"21","author":"D Matye","year":"2024","unstructured":"Matye D, Leak J, Woolbright BL, Taylor JA. Preclinical models of bladder cancer: BBN and beyond. Nat Rev Urol. 2024;21(12):723\u201334.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3677_CR14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","volume":"25","author":"C Segovia","year":"2019","unstructured":"Segovia C, San Jos\u00e9-En\u00e9riz E, Munera-Maravilla E, Mart\u00ednez-Fern\u00e1ndez M, Garate L, Miranda E, et al. Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073\u201381.","journal-title":"Nat Med"},{"issue":"1","key":"3677_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-18-0685","volume":"25","author":"C Rubio","year":"2019","unstructured":"Rubio C, Mart\u00ednez-Fern\u00e1ndez M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, et al. CDK4\/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res. 2019;25(1):390\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3677_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1242\/dev.01148","volume":"131","author":"S Ruiz","year":"2004","unstructured":"Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A, et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development. 2004;131(11):2737\u201348.","journal-title":"Development"},{"issue":"21","key":"3677_CR17","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1158\/0008-5472.CAN-05-1853","volume":"65","author":"S Ruiz","year":"2005","unstructured":"Ruiz S, Santos M, Lara MF, Segrelles C, Ballest\u00edn C, Paramio JM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res. 2005;65(21):9678\u201386.","journal-title":"Cancer Res"},{"issue":"1","key":"3677_CR18","first-page":"53","volume":"58","author":"A Ram\u00edrez","year":"1994","unstructured":"Ram\u00edrez A, Bravo A, Jorcano JL, Vidal M. Sequences 5\u2019 of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation. 1994;58(1):53\u201364.","journal-title":"Differentiation"},{"issue":"1","key":"3677_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/gene.20025","volume":"39","author":"A Ramirez","year":"2004","unstructured":"Ramirez A, Page A, Gandarillas A, Zanet J, Pibre S, Vidal M, et al. A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis. 2004;39(1):52\u20137.","journal-title":"Genesis"},{"issue":"12","key":"3677_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11934-019-0949-6","volume":"20","author":"M Aron","year":"2019","unstructured":"Aron M. Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes. Curr Urol Rep. 2019;20(12):80.","journal-title":"Curr Urol Rep"},{"issue":"4","key":"3677_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/00313020152635829","volume":"33","author":"R Chetty","year":"2001","unstructured":"Chetty R, Clarke B. Myxoid invasive papillary urothelial carcinoma of the bladder and urethra. Pathology. 2001;33(4):515\u20138.","journal-title":"Pathology"},{"issue":"28","key":"3677_CR22","doi-asserted-by":"publisher","first-page":"e21204","DOI":"10.1097\/MD.0000000000021204","volume":"99","author":"TT Tao","year":"2020","unstructured":"Tao TT, Chen J, Hu Q, Huang XJ, Fu J, Lv BD, et al. Urothelial carcinoma of the bladder with abundant myxoid stroma: A case report and literature review. Medicine. 2020;99(28):e21204.","journal-title":"Medicine"},{"issue":"10","key":"3677_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.humpath.2009.04.002","volume":"40","author":"F Tavora","year":"2009","unstructured":"Tavora F, Epstein JI. Urothelial carcinoma with abundant myxoid stroma. Hum Pathol. 2009;40(10):1391\u20138.","journal-title":"Hum Pathol"},{"issue":"10","key":"3677_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.humpath.2009.02.016","volume":"40","author":"A Lopez-Beltran","year":"2009","unstructured":"Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009;40(10):1461\u20136.","journal-title":"Hum Pathol"},{"issue":"1","key":"3677_CR25","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, et al. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020;10(1):9743.","journal-title":"Sci Rep"},{"issue":"6","key":"3677_CR26","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","volume":"27","author":"CC Guo","year":"2019","unstructured":"Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019;27(6):1781\u2013e17934.","journal-title":"Cell Rep"},{"issue":"9","key":"3677_CR27","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.1007\/s11033-023-08689-7","volume":"50","author":"L Schwarzova","year":"2023","unstructured":"Schwarzova L, Varchulova Novakova Z, Danisovic L, Ziaran S. Molecular classification of urothelial bladder carcinoma. Mol Biol Rep. 2023;50(9):7867\u201377.","journal-title":"Mol Biol Rep"},{"issue":"29","key":"3677_CR28","doi-asserted-by":"publisher","first-page":"47595","DOI":"10.18632\/oncotarget.17394","volume":"8","author":"S Rinaldetti","year":"2017","unstructured":"Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, et al. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. 2017;8(29):47595\u2013606.","journal-title":"Oncotarget"},{"issue":"11","key":"3677_CR29","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1158\/0008-5472.CAN-08-2816","volume":"69","author":"DC Tomlinson","year":"2009","unstructured":"Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 2009;69(11):4613\u201320.","journal-title":"Cancer Res"},{"key":"3677_CR30","doi-asserted-by":"crossref","unstructured":"Antonova O, Hammoudeh Z, Yordanova Z, Mladenov B. Determination of expression level of AP1S1, CDK9, FIGF and HDAC11 genes in bladder tumors for aggressive phenotype characterization. Biotechnol Biotechnol Equip. 2023;37(1).","DOI":"10.1080\/13102818.2023.2253926"},{"issue":"1","key":"3677_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ni.1673","volume":"10","author":"A Villagra","year":"2009","unstructured":"Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10(1):92\u2013100.","journal-title":"Nat Immunol"},{"issue":"2","key":"3677_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.01.005","volume":"359","author":"X Ning","year":"2015","unstructured":"Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, et al. DNMT1 and EZH2 mediated methylation silences the microRNA-200b\/a\/429 gene and promotes tumor progression. Cancer Lett. 2015;359(2):198\u2013205.","journal-title":"Cancer Lett"},{"issue":"1","key":"3677_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13148-019-0786-y","volume":"11","author":"Y Hu","year":"2019","unstructured":"Hu Y, Wu F, Liu Y, Zhao Q, Tang H. DNMT1 recruited by EZH2-mediated silencing of miR-484 contributes to the malignancy of cervical cancer cells through MMP14 and HNF1A. Clin Epigenetics. 2019;11(1):186.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"3677_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12864-015-1450-3","volume":"16","author":"J Earl","year":"2015","unstructured":"Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodr\u00edguez-Santiago B, M\u00e9ndez-Pertuz M, Auer H, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2015;16(1):403.","journal-title":"BMC Genomics"},{"issue":"4","key":"3677_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al. Epigenetic Antagonism between Polycomb and SWI\/SNF Complexes during Oncogenic Transformation. Cancer Cell. 2010;18(4):316\u201328.","journal-title":"Cancer Cell"},{"issue":"11","key":"3677_CR36","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1021\/acs.biochem.5b01191","volume":"55","author":"C Kadoch","year":"2016","unstructured":"Kadoch C, Copeland RA, Keilhack H. PRC2 and SWI\/SNF Chromatin Remodeling Complexes in Health and Disease. Biochemistry. 2016;55(11):1600\u201314.","journal-title":"Biochemistry"},{"issue":"7668","key":"3677_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"4","key":"3677_CR38","doi-asserted-by":"publisher","first-page":"188912","DOI":"10.1016\/j.bbcan.2023.188912","volume":"1878","author":"S Zhang","year":"2023","unstructured":"Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory effects of CDK4\/6 inhibitors. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188912.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3677_CR39","doi-asserted-by":"crossref","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29443960\/.\u00a0Cited 2026 Feb 6.","DOI":"10.1038\/nature25501"},{"key":"3677_CR40","doi-asserted-by":"crossref","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28650338\/.\u00a0 Cited 2026 Feb 6.","DOI":"10.1172\/JCI91190"},{"key":"3677_CR41","doi-asserted-by":"crossref","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31686036\/. Cited 2026 Feb 6.","DOI":"10.1038\/s41591-019-0628-7"},{"key":"3677_CR42","doi-asserted-by":"crossref","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67\u201376. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27939400\/.\u00a0Cited 2026 Feb 6.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"issue":"6","key":"3677_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1101\/gad.1772909","volume":"23","author":"AM Puzio-Kuter","year":"2009","unstructured":"Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675\u201380.","journal-title":"Genes Dev"},{"issue":"12","key":"3677_CR44","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/cancers16122245","volume":"16","author":"E Desponds","year":"2024","unstructured":"Desponds E, Kioseoglou K, Zdimerova H, Ongaro M, Verdeil G, Leblond MM. Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer. Cancers (Basel). 2024;16(12):2245.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"3677_CR45","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1158\/0008-5472.CAN-21-1254","volume":"81","author":"S Park","year":"2021","unstructured":"Park S, Rong L, Owczarek TB, Bernardo M, Di, Shoulson RL, Chua CW, et al. Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. Cancer Res. 2021;81(20):5161\u201375.","journal-title":"Cancer Res"},{"key":"3677_CR46","doi-asserted-by":"crossref","unstructured":"Gao Y, Shen J, Choy E, Mankin H, Hornicek F, Duan Z. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss. Cellular oncology (Dordrecht, Netherlands). 2017;40(3):209\u201318. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28243976\/. Cited 2026 Feb 5.","DOI":"10.1007\/s13402-017-0316-x"},{"key":"3677_CR47","doi-asserted-by":"crossref","unstructured":"Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Gra\u00f1a X et al. Proliferative Suppression by CDK4\/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells. Gastroenterology. 2010;138(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20100483\/.\u00a0Cited 2026 Feb 5.","DOI":"10.1053\/j.gastro.2010.01.007"},{"issue":"22","key":"3677_CR48","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-14-1218","volume":"74","author":"M Santos","year":"2014","unstructured":"Santos M, Mart\u00ednez-Fern\u00e1ndez M, Due\u00f1as M, Garc\u00eda-Escudero R, Alfaya B, Villacampa F, et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014;74(22):6565\u201377.","journal-title":"Cancer Res"},{"key":"3677_CR49","doi-asserted-by":"crossref","unstructured":"Pirici D, Mogoanta L, Kumar-Singh S, Pirici I, Margaritescu C, Simionescu C et al. Antibody Elution Method for Multiple Immunohistochemistry on Primary Antibodies Raised in the Same Species and of the Same Subtype. Journal of Histochemistry and Cytochemistry. 2009;57(6):567. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2690408\/.\u00a0\u00a0Cited 2026 Feb 6.","DOI":"10.1369\/jhc.2009.953240"},{"issue":"11","key":"3677_CR50","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. PLoS ONE. 2023;18(11):e0294236.","journal-title":"PLoS ONE"},{"issue":"43","key":"3677_CR51","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3677_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"17","key":"3677_CR53","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1093\/nar\/gkab554","volume":"49","author":"K Tang","year":"2021","unstructured":"Tang K, Ji X, Zhou M, Deng Z, Huang Y, Zheng G, et al. Rank-in: enabling integrative analysis across microarray and RNA-seq for cancer. Nucleic Acids Res. 2021;49(17):e99\u201399.","journal-title":"Nucleic Acids Res"},{"key":"3677_CR54","doi-asserted-by":"crossref","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1(3).","DOI":"10.1002\/cpz1.90"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03677-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03677-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03677-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:40:21Z","timestamp":1781635221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03677-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3677"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03677-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee of Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT) and the competent regional authority (Animal Welfare Department of the Comunidad de Madrid; PROEX 088\/15 and 150.8\/21), in compliance with Directive 2010\/63\/EU and Spanish national regulations (RD 53\/2013) for the protection of animals used for scientific purposes. All procedures were conducted in accordance with institutional guidelines to minimize animal suffering. The maximal tumor size permitted in adult mice was approximately 1.5\u00a0cm\u00b3, and we confirmed that this limit was not exceeded. Cages were randomized to experimental groups to minimize environmental bias, and all observers were blinded to the experimental conditions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}